Vanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) reported positive topline results from a Phase 3 study of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.